BRUCE R BISTRIAN, M.D.
Osteopathic Medicine in Boston, MA

7150996, Dec 19, 2006

Jun 27, 2003

10/606959

David F. Nicoli - Goleta CA, US
David F. Driscoll - Bridgewater MA, US
Bruce R. Bistrian - Ipswich MA, US

Stable Solutions, Inc. - Goleta CA

G01N 33/00

436 69, 436164, 436176, 422 73, 422 681, 73 5301, 73 6143, 73 6148, 73 6171, 73 6441, 73 6443

A method and apparatus for determining the stability of dispersions and emulsions accelerates the onset of significant particle agglomeration in a sample by stressing the sample by reducing the height of the interparticle potential energy barrier between the particles. This is achieved by adding one or more of three stress factors: changing the pH of the sample to reduce the surface charge on the particles; adding an adsorbing electrolyte so that ions of the appropriate charge are adsorbed onto the surfaces of the particles to reduce the net charge on the particles; and applying a monovalent, divalent, or trivalent salt to partially screen electrostatic repulsions between the charged particles. In a preferred embodiment, the increase in agglomeration is detected with single particle detection, such as SPOS, to generate a PSD from which a figure of merit is derived. Another embodiment detects turbidity or light scattering to generate a value X indicative of the extent of agglomeration.

5962712, Oct 5, 1999

Apr 23, 1997

8/839086

Stephen Joseph DeMichele - Dublin OH
Michael Donald Karlstad - Knoxville TN
Bruce Ryan Bistrian - Ipswich MA
Edward Anthony Mascioli - Needham MA

Abbott Laboratories - Abbott Park IL

C07C 5300

554224

There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series "2" prostanoids and elevating the levels of series "1" and "3" prostanoids. The n-3 fatty acid residue enhances the level of series "1" prostanoids as well as increases the production of series "3" prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.

5081105, Jan 14, 1992

Jan 25, 1990

7/470164

Bruce R. Bistrian - Ipswich MA

New England Deaconess Hospital Corporation - Boston MA

A61K 3700, A61K 3122, A61K 3123

514 2

Disclosed is a method of treating cancer using nutritional support therapy by administration of a structured lipid containing both. omega. 3 fatty acids and medium-chain fatty acids. The therapy may be used as total parenteral nutrition or as a nutritional supplement. The addition of tumor necrosis factor may also be beneficial.

5902797, May 11, 1999

Nov 10, 1997

8/966829

Stacey J. Bell - Belmont MA
R. Armour Forse - Brookline MA
Bruce R. Bistrian - Ipswich MA
Robert C. Jones - Belmont MA

Beth Israel Deaconess Medical Center - Boston MA
Medical Foods, Inc. - Cambridge MA

A23L1/30

514 54

A nutritional supplement comprising approximately from about 5 to about 25 grams carbohydrate; approximately from about 1 to about 25 grams protein; and approximately from about 1 to about 10 grams fat, for use in treating low appetite that may result in weight loss, is described.

4512974, Apr 23, 1985

Dec 8, 1982

6/447984

Lyle L. Moldawer - Waban MA
George L. Blackburn - Cambridge MA
Bruce R. Bistrian - Ipswich MA

A61K 3516

424101

Exogenous LEM (Leukocyte Endogenous Mediator, also referred to as endogenous pyrogen) is parenterally administered to humans who are protein malnourished and are to undergo surgery, in order to preinitiate and then maintain the normal metabolic responses to the tissue damage occurring during surgery, and thereby promote the normal metabolic response by the human (patient).

5993221, Nov 30, 1999

May 1, 1997

8/847036

Bruce R. Bistrian - Ipswich MA

Beth Israel Deaconess Medical Center, Inc. - Boston MA

A61K 4744, A61K 9127, A61M 500

434429

A novel formulation which contains about 2-60% by calories of a C. sub. 20 or longer. omega. 3 fatty acid moiety and about 2-60% by calories of an arachidonic acid moiety has been developed. This formulation is particularly useful for restoring arachidonic acid levels, increasing immunity or minimizing risk of infection in critically ill patients, and treating functional essential fatty acid deficiency in patients suffering from end stage liver disease. A structured lipid which has a C. sub. 20 or longer. omega. 3 fatty acid moiety and an arachidonic acid moiety has also been developed.

5386832, Feb 7, 1995

Jun 11, 1993

8/075662

David A. Wagner - Acton MA
Martin A. Baker - Mahwah NJ
Peter A. Burke - Belmont MA
R. Amour Forse - Brookline MA
John D. Palombo - Medfield MA
Bruce R. Bistrian - Ipswich MA

New England Deaconess Hospital - Boston MA
Metabolics Solutions, Inc. - Acton MA

A61B 508, A61B 600

128665

A test for determining hepatic function has been developed. This test uses oral administration of isotope labeled phenylalanine or tyrosine, particularly. sup. 13 C-phenylalanine, in a rapid breath test. In the preferred mode, the breath sample is analyzed using a mass spectrometer and compared with a standard. The breath test provides a dynamic rather than static determination of hepatic function and can be used for both early and late stage liver problems.

6143731, Nov 7, 2000

Jul 27, 1999

9/361831

Spiros Jamas - Boston MA
D. Davidson Easson - Shrewsbury MA
Bruce R. Bistrian - Ipswich MA

The Collaborative Group, Ltd. - Stony Brook NY

A01N 4304, A01N 3700, C12Q 100

514 54

Compositions useful in the treatment of dietary disorders, and as dietary additives to provide a source of fiber and of short chain fatty acids, to reduce the level of serum cholesterol, increase HDL cholesterol levels and as bulking agents in humans and animals, as well as methods of use therefor are described. The compositions and methods are based on whole. beta. -glucans.

4847296, Jul 11, 1989

Mar 20, 1987

7/028278

Vigen K. Babayan - Waban MA
George L. Blackburn - Jamiaca Plains MA
Bruce R. Bistrian - Ipswich MA

A61K 3123

514552

Chemically synthesized structured triglycerides (lipids) for enteral administration as the lipid calorie source, is subjects undergoing severe metabolic stress.